Novartis consolidates post spin off - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Novartis consolidates post spin off

Aug 23, 2000

An over 40% rise in the stock price (over two months) is the market’s way of looking at the spin off of the agrochemical division by Novartis India. (The international parent Novartis AG has proposed the separation of its agrochemical arm and its merger with the agrochemical arm of Astra Zeneca to form a new company Syngenta. In India too the same process is underway.)

The reasons for this are not far to seek. The healthcare business (this includes the vision care division and the animal health division) is not an asset heavy business since Novartis India outsources most of its production. The top 8 brands of the company contribute almost 49% of its formulation sales (see table).

Product profile
Major ProductsTherapeutic area% of pharma sales
VoveranAnti–inflammatory & pain18.0%
TegretolCentral Nervous System (anti–epileptic)7.0%
MethergineGenito–Urinary System6.0%
OtrivinNasal Decongestant4.0%
MacalvitCalcium Supplement3.0%

The overall operating margins of the company, which were around 17% can be expected to increase to around 20% post the hive off of the agrochemical division. Also, the company would be able to reduce its working capital requirements since the inventory days and debtors days can almost be halved from the present levels of 70 days and 55 days respectively.

Consequently, the return on capital would zoom to a mind boggling 64% and the return on equity would improve to 42% in FY2001. Besides, the company has launched five new products over the last two years (see table) all of which are out of the purview of the Drug Price Control Order. This can be expected to improve the margins further.

Sales/Assets (times)8.817.8
ROCE is profit before interest and tax divided by the debt plus equity at the end of the year

The improvement in profits, the removal of a seasonal business, the introduction of new products coupled with the almost zero debt status of the company should spell good times for the company. The stock quotes at Rs 879 (52 week range: 1436/618) an earning multiple of 40 times its FY01 earnings. These can be estimated to jump almost 50% over the next two years.

New Products introduced over the last two years
New ProductsPurpose
Femarafor treatment of advanced breast cancer
Exelonfor management of Alzheimer's disease
Epitrilfor treatment of epilepsy and panic disorders
PZA–1000for treatment of TB
3FDfor treatment of TB

Another trigger for the stock could be a sizeable sum from the grant of development rights at its real estate in Goregaon (a suburb of Mumbai). Last year, the company granted development rights on this real estate and this fetched the company an amount of Rs 66 m. (Novartis’ real estate can fetch it around $ 1.5 bn if it were to give development rights for its entire estate.)

The only possible dampener to the stock valuations could be the presence of two 100% subsidiaries of the parent, which would be used to launch nutritional products in the future.

Equitymaster requests your view! Post a comment on "Novartis consolidates post spin off ". Click here!


More Views on News

Sorry! There are no related views on news for this company/sector.

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

Can the Nifty Fall to 10,200? (Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms


Sep 25, 2020 (Close)